Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMDZ
CUSIPN/A
Phone206-682-0645
Debt
Debt-to-Equity RatioN/A
Current Ratio21.18
Quick Ratio21.08
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.20 million
Price / Sales29.41
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book1.52
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-51,860,000.00
Net Margins-2,352.98%
Return on Equity-52.00%
Return on Assets-45.88%
Miscellaneous
Employees56
Outstanding Shares48,130,000
Immune Design (NASDAQ:IMDZ) Frequently Asked Questions
What is Immune Design's stock symbol?
Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."
How were Immune Design's earnings last quarter?
Immune Design Corp (NASDAQ:IMDZ) released its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. The biotechnology company earned $0.50 million during the quarter, compared to analysts' expectations of $1.83 million. Immune Design had a negative net margin of 2,352.98% and a negative return on equity of 52.00%. View Immune Design's Earnings History.
When is Immune Design's next earnings date?
What price target have analysts set for IMDZ?
4 brokers have issued twelve-month target prices for Immune Design's shares. Their forecasts range from $8.00 to $20.00. On average, they expect Immune Design's stock price to reach $12.6667 in the next year. View Analyst Ratings for Immune Design.
Who are some of Immune Design's key competitors?
Some companies that are related to Immune Design include Dova Pharmaceuticals (DOVA), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), ANI Pharmaceuticals Inc Common Stock (ANIP), Theratechnologies (THERF), Vectura Group (VEGPF), Evolus (EOLS), Urogen Pharma (URGN), Amphastar Pharmaceuticals (AMPH), NuCana (NCNA), Abeona Therapeutics (ABEO), Homology Medicines (FIXX), Inflarx (IFRX), AMAG Pharmaceuticals (AMAG) and Arcus Biosciences (RCUS).
Who are Immune Design's key executives?
Immune Design's management team includes the folowing people:
- Dr. Carlos V. Paya, CEO, Pres & Director (Age 59)
- Mr. Stephen R. Brady, Exec. VP of Strategy & Fin. (Age 48)
- Dr. Jan Henrik Ter Meulen, Chief Scientific Officer (Age 55)
- Mr. Christopher Whitmore CPA, VP of Fin. & Admin.
- Dr. Wayne R. Gombotz, Chief Devel. Officer (Age 59)
Has Immune Design been receiving favorable news coverage?
News articles about IMDZ stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Design earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 44.16 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Immune Design's major shareholders?
Immune Design's stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (8.53%), BlackRock Inc. (3.98%), JPMorgan Chase & Co. (1.75%), Dimensional Fund Advisors LP (0.40%) and DRW Securities LLC (0.08%). Company insiders that own Immune Design stock include Carlos V Paya, Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Meulen Jan Henrik Ter, Peter Svennilson, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design.
Which institutional investors are selling Immune Design stock?
IMDZ stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Immune Design company stock in the last year include Carlos V Paya, Meulen Jan Henrik Ter, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Insider Buying and Selling for Immune Design.
Which institutional investors are buying Immune Design stock?
IMDZ stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Dimensional Fund Advisors LP, BlackRock Inc. and DRW Securities LLC. Company insiders that have bought Immune Design stock in the last two years include Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Peter Svennilson and Stephen R Brady. View Insider Buying and Selling for Immune Design.
How do I buy shares of Immune Design?
Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Design's stock price today?
One share of IMDZ stock can currently be purchased for approximately $4.40.
How big of a company is Immune Design?
Immune Design has a market capitalization of $214.16 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.
How can I contact Immune Design?
Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]
MarketBeat Community Rating for Immune Design (IMDZ)
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
